食管癌血管生成的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.01.010

摘要/Abstract

摘要： 食管癌的高侵袭性与血管生成密切相关，并伴随微血管密度、血管内皮生长因子、血管生成相关因子及其受体表达水平的改变。研究发现，血清中高水平的血管生成相关因子与食管癌患者疗效不佳及预后不良密切相关，提示其可作为食管癌治疗的新靶点，值得进一步深入探索。

关键词: 食管肿瘤, 新生血管化, 病理性, 血管内皮生长因子类, 靶向治疗

Abstract: High invasive potential of esophageal carcinoma is often associated with angiogenesis, accompanied by the changes of microvessel density, vascular endothelial growth factor, angiogenic factors and their receptors. Studies show that there are significant correlations between increased serum levels of angiogenic factors and insufficient treatment response and poor prognosis in patients with esophageal cancer. Such angiogenesisrelated molecules may represent novel targets in treating esophageal cancer, which deserve further exploration.

Key words: Esophageal neoplasms, Neovascularization, pathologic, Vascular endothelial growth factors, Targeted therapy

王伟, 胡冰, 何义富. 食管癌血管生成的研究进展[J]. 国际肿瘤学杂志, 2014, 41(1): 31-34.

Wang Wei, Hu Bing, He Yifu. Tumor angiogenesis in esophageal cancer[J]. Journal of International Oncology, 2014, 41(1): 31-34.

参考文献

［1］ Hong L, Li S, Han Y, et al. Angiogenesisrelated molecular targets in esophageal cancer［J］. Expert Opin Investig Drugs, 2011, 20(5):637644. ［2］ Norguet E, Dahan L, Seitz JF. Targetting esophageal and gastric cancers with monoclonal antibodies［J］. Curr Top Med Chem, 2012, 12(15):16781682. ［3］ Barzi A, Lenz HJ. Angiogenesisrelated agents in esophageal cancer［J］. Expert Opin Biol Ther, 2012, 12(10):13351345. ［4］孙其恺, 吕阳, 王伟. periostin与肿瘤相关研究进展［J］. 中华外科杂志, 2013, 51(7):659661. ［5］ Jiang JT, Zhang LF, Zhou B, et al. Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis［J］. Asian Pac J Cancer Prev, 2012, 13(7):33793383. ［6］王确, 周儒白, 田李星, 等. 血管内皮生长因子与食管癌预后相关性的Meta分析［J］. 中国循证医学杂志, 2013, 13(5):553559. ［7］ Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and metaanalysis［J］. Cancer Epidemiol Biomarkers Prev, 2012, 21(7):11261134. ［8］ Lin C, Song L, Gong H, et al. Nkx28 downregulation promotes angiogenesis and activates NFκB in esophageal cancer［J］. Cancer Res, 2013, 73(12):36383648. ［9］ Sakurai T, Okumura H, Matsumoto M, et al. The expression of LC3 is related to tumor suppression through angiogenesis in esophageal cancer［J］. Med Oncol, 2013, 30(4):701. ［10］ Chen MF, Chen PT, Lu MS, et al. IL6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus［J］. Mol Cancer, 2013, 12:26. ［11］ Wang LD, Zhou FY, Li XM, et al. Genomewide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54［J］. Nat Genet, 2010, 42(9):759763. ［12］ Abnet CC, Freedman ND, Hu N, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma［J］. Nat Genet, 2010, 42(9):764767. ［13］ Wu C, Hu Z, He Z, et al. Genomewide association study identifies three new susceptibility loci for esophageal squamouscell carcinoma in Chinese populations［J］. Nat Genet, 2011, 43(7):679684. ［14］ Wong GS, Lee JS, Park YY, et al. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment［J］. Oncogenesis, 2013, 2:e59. ［15］ Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma［J］. Cancer, 2001, 92(3):663669. ［16］ Kozlowski M, Kowalczuk O, Milewski R, et al. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer［J］. Eur J Cardiothorac Surg, 2010, 38(3):260267. ［17］季文豪, 凌志强, 毛伟敏. 食管癌治疗敏感基因单核苷酸多态性［J］. 国际肿瘤学杂志, 2011, 38(12):923926. ［18］ Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis［J］. Clin Cancer Res, 2009, 15(14):46804685. ［19］ Lurje G, Leers JM, Pohl A, et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus［J］. Ann Surg, 2010, 251(5):857864. ［20］ Lyros O, Mueller A, Heidel F, et al. Analysis of antiproliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multireceptor tyrosine kinase pathways［J］. Int J Cancer, 2010, 127(5):11971208. ［21］ Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer［J］. Expert Opin Emerg Drugs, 2009, 14(2):329339. ［22］ Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation［J］. Cancer Res, 1999, 59(14):33743378. ［23］ Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumabinduced normalization of blood vessels in tumors hampers antibody uptake［J］. Cancer Res, 2013, 73(11):33473355. ［24］ Liu J, Li Z, Cui J, et al. Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas［J］. Tumour Biol, 2012, 33(2):495505. ［25］ Goscinski MA, Nesland JM, Giercksky KE, et al. Primary tumor vascularity in esophagus cancer. CD34 and HIF1α expression correlate with tumor progression［J］. Histol Histopathol, 2013, 28(10):13611368.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[6]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[7]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[8]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[9]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[10]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[11]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[12]	王婷, 李文倩, 解友邦. 低氧与急性髓系白血病细胞氧感受通路的相关性[J]. 国际肿瘤学杂志, 2023, 50(8): 503-507.
[13]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[14]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[15]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.